Synonyms: CLM-001 | IPN-60120 | IPN60120 | R-667 | R667 | RG-667 | Ro-3300074 | Sohonos®
palovarotene is an approved drug (Canada (2022), FDA (2023))
Compound class:
Synthetic organic
Comment: Palovarotene is an orally bioavailable, retinoic acid receptor gamma (RAR-γ) agonist. This compound was originally investegated for its potential to repair alveolar damage in emphysema and COPD [1,8], but it failed to demonstrate significant clinical efficacy. Ipsen acquired palovarotene when it purchased Clementia Pharmaceuticals in 2019, and they repurposed palovarotene for potential to reduce heterotopic ossification in patients with fibrodysplasia ossificans progressiva (FOP) [6,9].
|
|
Bioactivity Comments |
Palovarotene dose-dependently suppresses heterotopic ossification in mice [7]. We have been unable to find a publicly available affinity value for this agonist at its proposed primary target, retinoic acid receptor gamma (RARG), so have tagged the primary target based on biological evidence. |
Selectivity at nuclear hormone receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|